Technology | Computed Tomography (CT)

Canon Medical Systems USA Inc. this week received U.S. Food and Drug Administration (FDA) clearance for the Aquilion Precision system, which it calls the world’s first Ultra-High Resolution computed tomography (UHR CT) system. The system can resolve anatomy as small as 150 microns and is designed to provide more than twice the resolution, typically seen only in cath labs. Containing an all-new detector as well as tube, gantry and reconstruction technologies, the system may make it possible to help expand visualization of disease thanks to new features that offer improved image detail.

Home April 13, 2018
Home
News | Implantable Cardioverter Defibrillator (ICD)

April 13, 2018 — Medical advice about implanted cardiac defibrillators obtained via an online message board appears to ...

Home April 13, 2018
Home
News | Implantable Cardioverter Defibrillator (ICD)

Biotronik U.S. and Aziyo announced a strategic agreement allowing Biotronik to distribute Aziyo's CanGaroo extracellular matrix (ECM) cardiovascular implantable electronic device (CIED) envelopes in the United States. BioEnvelope will be available from Biotronik starting in April 2018.

Home April 12, 2018
Home
News | Hemodynamic Support Devices

French medical technology company CorWave announced it has been awarded almost $3.5 million in financing for its R&D program NovaPulse in the Silver Economy category. This is part of phase 2 of France’s Concours Mondial d'Innovation or Worldwide Innovation Challenge.

Home April 12, 2018
Home
News | Congenital Heart

Women who give birth to infants with congenital heart defects may have an increased risk of cardiovascular hospitalizations later in life, according to new research in the American Heart Association’s journal Circulation.

Home April 12, 2018
Home
News

Medtronic plc announced one-year results from the CRYO4PERSISTENT AF study of ablation with the Arctic Front Advance Cryoballoon to isolate the pulmonary veins in patients with symptomatic persistent atrial fibrillation (AF). The Arctic Front Advance Cyroablation System is not approved for treating persistent AF in the United States.

Home April 12, 2018
Home
Blog | Cath Lab

The biggest workplace concern for interventional cardiologists and cath lab staff is their daily exposure to ionizing ...

Home April 12, 2018
Home
News | Optical Coherence Tomography (OCT)

Abbott today announced the initiation of a clinical trial evaluating long-term outcomes of patients who undergo stent implantation guided by optical coherence tomography (OCT) compared to angiography. The trial (ILUMIEN IV) is the first large-scale randomized global study using Abbott's OCT imaging in patients with high-risk, complex coronary artery disease. Patients in the study will be randomized to either OCT-guided or traditional angiography to guide placement of one or more Xience everolimus-eluting coronary stents.

Home April 11, 2018
Home
Technology | Vascular Closure Devices

https://www.dicardiology.com/channel/vascular-closure-devicesCardiva Medical announced the company received U.S. Food and Drug Administration (FDA) approval for an expanded indication of the Vascade Vascular Closure System. Already approved for use in arterial closure, Vascade is now FDA-approved for use in 5-7F femoral venous closures as well. This expansion creates an opportunity to better treat patients undergoing interventional cardiac catheterization procedures, while also greatly increasing the available market for the device.

Home April 10, 2018
Home
News | Heart Valve Technology

University Hospitals Harrington Heart & Vascular Institute has officially opened the APOLLO trial, implanting the first Intrepid transcatheter mitral valve replacement system in the study. Alan Markowitz, M.D., and Guilherme F. Attizzani, M.D., performed the procedure, the first in the state of Ohio.

Home April 06, 2018
Home
News | Pharmaceuticals

Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint with a statistically significant reduction in all-cause mortality plus frequency of cardiovascular-related hospitalizations compared to placebo at 30 months. The preliminary safety data showed that tafamidis was generally well tolerated in this population and no new safety signals were identified.1

Home April 06, 2018
Home
News | Hypertension

YMCA of the USA (Y-USA) and the American Heart Association (AHA) are combining efforts to help more people better manage their blood pressure. Beginning this spring, more than 100 clinics participating in the Target: BP initiative will be able to refer qualified patients to enroll at no cost in the YMCA’s Blood Pressure Self-Monitoring program.

Home April 05, 2018
Home
News | Stroke

April 5, 2018 — Medical imaging company Brainomix has attracted £7m ($9.8 million) of investment to bring its artificial ...

Home April 05, 2018
Home
News | Cardiovascular Business

April 5, 2018 — Diagnostic and Interventional Cardiology (DAIC) magazine received the 2018 Jesse H. Neal Award for Best ...

Home April 05, 2018
Home
News | Heart Failure

The Ohio State University Wexner Medical Center will establish the nation’s first center dedicated to treating those with heart failure and arrhythmia with gifts totaling $18 million from Bob and Corrine Frick.

Home April 04, 2018
Home
Subscribe Now